Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-05-09
2000-08-08
LeGuyader, John L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
424 9321, 435 691, 4353201, 435455, 435458, A61K 4800
Patent
active
061002437
ABSTRACT:
The present invention is directed to methods of sensitizing a human tumor cell with adenovirus E1A. The methods involve treating a human tumor cell by, first, introducing into the tumor cell nucleic acid encoding a polypeptide having adenovirus E1A activity, expressing the E1A active polypeptide in the cell, and then either contacting the E1A expressing tumor cell with a chemotherapeutic agent or irradiating the E1A-expressing tumor cell. The invention also provides methods of enhancing a subject's response to chemotherapy or irradiation by introducing into a subject's tumor cells nucleic acid encoding a polypeptide having adenovirus E1A activity, expressing the E1A active polypeptide in the cells and finally, administering either a chemotherapeutic agent or irradiation. The invention also provides a method of treating cancer.
REFERENCES:
patent: 5516631 (1996-05-01), Frisch
patent: 5651964 (1997-07-01), Hung et al.
patent: 5747964 (1998-05-01), Roth et al.
patent: 5776743 (1998-07-01), Frisch
Sanchez-Prieto et al., Oncogene, vol. 13, pp. 1083-1092 1996.
Stein J. (in: Internal Medicine, 4th edition, Mosby Year Book, pp. 699-715) 1993.
Mastrangleo et al. reference (Seminars in Oncology, 1996, vol. 23, 1:4-21) 1996.
Crystal, Science, vol. 270:404-409, 1995.
Coghlan (New Scientist, Nov. 1995, vol. 148:14-15).
Sanchez-Prieto et al., "Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes." Int. J. Cancer, 60:235-243 (1995).
Gruber and Greil, "Apoptosis and therapy of maligant disease of the hematopoietic system." Int. Arch. Allergy Immunol., 105:368-373 (1994).
Sinkovics and Horvath, "Apoptosis by Genetic Engineering." Leukemia, 8:S98-S102 (1994).
Canman and Kastan, "Induction of apoptosis by tumor suppressor genes and oncogenes." Cancer Biol., 6:17-25 (1995).
Martin and Green, "Apoptosis as a goal of cancer therapy." Current Opinion in Oncology, 6:616-621 (1994).
Frisch, Steven M., "Antioncogenic effect of adenovirus E1A in human tumor cells." Proc. Natl. Acad. Sci. USA, 888:9077-9081 (1991).
Frisch and Francis, "Disruption of epithelial cell-matrix interactions induces apoptosis." J. Cell Biol., 124(4) :61-626 (1994).
Lowe et al., "p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents." Cell 74:957-967 (1993).
Rao et al., "The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bc1-2 proteins." Proc. Natl. Acad. Sci. USA, 89:7742-7746 (1992).
Evan et al., "Induction of apoptosis in fibroblasts by c-myc protein." Cell, 69:119-128 (1992).
Chen et al., "Induction by E1A oncogene expression of cellular susceptibility to lysis by TNF." Nature, 330:581-583 (1987).
Fanidi et al., "Cooperative interaction between c-myc and bc1-2 proto-oncogenes." Nature, 359:554-556 (1992).
Yu et al., "Adenovirus type E1A gene products act as transformation suppressors of the neu oncogene." Mol. Cell. Biol. 11:1745-1750 (1991).
Miller et al., "Improved retroviral vectors for gene transfer and expression." Biotechniques 7:980-990 (1989).
Yu et al., "Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A." Cancer Research 53:5784-5790 (1993).
Fujiwara et al., "induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene." Cancer Research 54:2287-2291 (1994).
Matsuzaki et al., "Mechanism of selective killing by dilinoleoylglycerol of cells transformed by the E1A gene of adenovirus type 12." Cancer Research 49:5702-5707 (1989).
Cook et al., "E1A ocogene expression level in sarcoma cells: an independent determinant of cytolytic susceptibility and tumor rejection." Oncogene 8:625-635 (1993)
Cook et al., "Expression of the adenovirus E1A oncogene during cell transformation is sufficient to induce susceptibility to lysis by host inflammatory cells." Proc. Natl. Acad. Sci. USA 83:6965-6969 (1986).
Cook et al., "Adenovirus E1A gene induction of susceptibility to lysis by natural killer cells and activated macrophages in infected rodent cells." J. Virology61(11):3510-3520 (1987).
Cook et al., "Differential induction of cytolytic susceptibility by E1A, myc, and ras oncogenes in immortalized cells." J. of Virology 63(8):3408-3415 (1989).
Cook et al., "Role of tumor necrosis faactor-.alpha.in E1A oncogene-induced susceptibility of neoplastic cells to lysis by natural killer cells and activated macrophages." J. of Immunology 142:4527-4534 (1989).
Duerksen-Hughes et al., "Adenovirus E1A renders infected cells sensitive to cytolysis by tumor necrosis factor." J. of Immunlolgy 143:4193-4200 (1989).
Walker et al., "E1A oncogene induction of cytolytic susceptiblilty eliminates sarcoma cell tumorigenicity." Proc. Natl. Acad. Sci. USA 88:6491-6495 (1991).
Blaese et al., "Vectors in cancer therapy: how will they deliver?" Cancer Gene Therapy, 2(4):291-297 (1995).
Culver et al., "Gene Therapy for Cancer." Trends in Genes, 10(5):174-178 (1994).
Brown, D., The Washington Post, Dec. 8, 1995, pp. A1 & A22.
Marshall, E., "Gene Therapy's Growing Pains." Science 269:1050-1055 (1995).
La Jolla Cancer Research Foundation
LeGuyader John L.
Nguyen Dave Trong
LandOfFree
Method of sensitizing tumor cells with adenovirus E1A does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of sensitizing tumor cells with adenovirus E1A, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of sensitizing tumor cells with adenovirus E1A will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1150248